Valerio Therapeutics SA
ALVIO.PA News Today: Stay Updated with the Latest Valerio Therapeutics SA News in Real Time
Find ALVIO.PA news now at Meyka AI. Stay informed with the latest Valerio Therapeutics SA stocks updates, including price news, market analysis, and expert insights.

ITRM Iterum Therapeutics plc NASDAQ Q4 2025 results 03 Apr 2026: Earnings drivers and outlook
ITRM stock closed at $0.03 on 03 Apr 2026 after Q4 2025 results. Read Meyka AI earnings spotlight and short-term outlook for ITRM stock

BTIG Maintains ALDX (Aldeyra Therapeutics) at Buy on Mar 17, 2026
BTIG maintains Buy on ALDX; ALDX analyst rating reviewed after Mar 17, 2026 note

Pre-Market: MMTX.SW stock rises 8.02% on SIX, watch volume for follow-through
MMTX.SW stock climbs 8.02% pre-market on SIX to CHF 0.35; technical oversold signals and Meyka AI forecast highlight near-term upside

Jefferies Maintains Buy for CTMX (CytomX Therapeutics) March 18, 2026
Jefferies maintained Buy on CTMX March 18, 2026. Read CTMX analyst rating, $16 PT, and Meyka AI grade B+

Jefferies Maintains Buy on Protagonist Therapeutics (PTGX) PT $121 Mar 2026
PTGX analyst rating update: Jefferies, Johnson Rice maintain Buy; PT $121 and royalty model cited

CHM.AX gains 100% pre-market on ASX: clinical catalysts and liquidity signal
Pre-market: CHM.AX stock jumps 100% to A$0.002 on ASX. We analyse drivers, valuation and Meyka AI forecast

CHF2.885 intraday (SIX): RLF.SW Relief Therapeutics may test CHF3.20 31 Mar 2026
RLF.SW stock intraday: CHF2.885, oversold bounce setup on SIX. Meyka AI forecast and technical outlook for Relief Therapeutics

ITRM Iterum Therapeutics plc NASDAQ -66% intraday 30 Mar 2026: heavy volume
ITRM stock down 66% intraday on NASDAQ 30 Mar 2026 with huge volume; short-term outlook and Meyka AI forecast compare risks and upside

NITI Aayog March 29: Gut Health Warning Puts Probiotics, Digital Care in Focus
NITI Aayog probiotics warning spotlights gut health, evidence-based products, digital health India, and generic medicines policy. We map investor catalysts, risks, and policy signals for India’s nutri